Five years ago, we marveled at the incredible advances in both medical and surgical dermatology. These included systemic retinoids for acne and keratinizing disorders, superpotent topical corticosteroids for even steroid-unresponsive dermatoses, photochemotherapy and narrow-band UVB phototherapy for psoriasis, and mycosis fungoides. They also included other difficult-to-treat skin problems, and sophisticated surgical modalities to improve photo-damaged skin and to help turn back the clock on skin aging in general. Five years ago, we celebrated, in these pages, 20 years of change in dermatology as reflected on the subjects that Dermatology Times covered for its readers.
The FDA approval, based on 36-week data from the phase 3 BRAVE-AA-PEDS trial, extends baricitinib access to patients as young as 12 years old with severe alopecia areata.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.